A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia.

Qian, Honglan; Gang, Dongxu; He, Xiaoyu; Jiang, Songfu

Qian, Honglan; Gang, Dongxu; He, Xiaoyu; Jiang, Songfu.

Afiliação

Qian H; Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Gang D; Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
He X; Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jiang S; Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Front Oncol ; 12: 1036437, 2022.

Article em En | MEDLINE | ID: mdl-36568202

Palavras-chave

T315I mutation; breakpoint cluster region protein and abelson tyrosine-protein kinase 1; chronic myeloid leukemia; olverembatinib; tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article